Physician profile
Uthan Vivek
NPI 1831109891
$11,181.71
in general payments reported to CMS, 2019-2025
42 companies · $558 in 2025
The $558 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,564 · 2020: $541 · 2021: $1,303 · 2022: $1,056 · 2023: $3,636 · 2024: $1,524 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,100 · Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,100.00 |
| Food and Beverage | $1,618.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Remington Medical, INC. | $4,100.00 | 2023-2024 | |
| Philips North America LLC | $1,696.10 | 2019-2023 | |
| Endologix LLC | $1,507.93 | 2019-2022 | |
| Medtronic, INC. | $768.66 | 2021-2025 | Venaseal, Endurant Iis, Interstim |
| Boston Scientific Corporation | $400.10 | 2019-2025 | Varithena Administration Pack, Eluvia |
| Cardiovascular Systems INC. | $301.31 | 2019-2023 | Diamondback Peripheral |
| Angiodynamics, INC. | $298.90 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $255.70 | 2019-2023 | Xarelto |
| Lemaitre Vascular, INC. | $235.13 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $233.34 | 2019-2024 | Fluency Endovascular Stent Graft |
| E.R. Squibb & Sons, L.L.C. | $132.09 | 2020-2024 | Eliquis |
| Cordis US Corp. | $130.73 | 2023 | Brite Tip Radianz, Mynx Control, Saber |
| Veryan Medical Incorporated | $102.88 | 2021-2023 | Biomimics 3d Vascular Stent System |
| Pfizer INC. | $93.32 | 2019-2022 | |
| Baxter Healthcare | $90.52 | 2024 | Renal - Chronic, Perclot |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imperative Care, INC | $85.27 | 2025 | Symphony Catheter |
| Penumbra, INC. | $53.70 | 2020-2023 | Penumbra System |
| Neuros Medical, INC. | $52.68 | 2025 | Altius |
| Avinger INC. | $51.88 | 2019 | |
| Getinge USA Sales, LLC | $48.43 | 2020-2022 | |
| Bone Support INC. | $46.23 | 2025 | Cerament G, Ceramentbone Void Filler |
| Reflow Medical INC | $45.06 | 2025 | |
| Inari Medical, INC. | $41.59 | 2019-2020 | |
| Cardiva Medical, INC. | $38.19 | 2023-2025 | Cardiva Vascade 5f Vcs, Cardiva Vascade 6/7f Vcs |
| Triad Life Sciences INC. | $34.29 | 2022 | |
| Silk Road Medical, INC. | $33.32 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Kerecis Limited | $31.30 | 2019-2020 | |
| Exeltis, USA INC. | $30.28 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.35 | 2019 | |
| W. L. Gore & Associates, INC. | $25.34 | 2021 | |
| Smith+Nephew, INC. | $24.40 | 2019 | |
| Mozarc Medical US LLC | $21.49 | 2024 | Permcath |
| Shockwave Medical, INC | $17.05 | 2021 | |
| Shield Therapeutics INC | $16.32 | 2022 | |
| Flowphysix INC | $16.25 | 2025 | Flowrunner |
| Argon Medical Devices, INC. | $15.98 | 2025 | Clot Management |
| Ekos Corporation | $15.19 | 2019 | |
| Terumo Medical Corporation | $14.73 | 2024 | Glidewire, Azur Cx Detachable |
| Therapeuticsmd, INC. | $14.25 | 2019 | |
| Cook Medical LLC | $13.96 | 2020 | |
| Lupin INC. | $13.81 | 2020 | |
| Reprise Biomedical, INC. | $8.66 | 2024 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uthan Vivek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.